Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

The study will consist of 4 clinic visits, including Screening/Baseline Visit 1 (Day 0, which
is anticipated to be the same date as the final visit in the lead-in P201 study) and visits
after 2, 6 and 12 weeks of treatment. The previous requirements in the lead-in study for
refraining from the use of certain concomitant medications and trauma-focused psychotherapies
will be relaxed. Patients may continue to take rescue therapy for sleep, as appropriate, or
they may utilize other medications as needed to help them sleep, per the judgment of the
investigator.

Eligible patients who provide written informed consent will take one TNX-102 SL tablet daily
at bedtime sublingually (under the tongue) for 12 weeks. All patients will be assigned to
receive tthe same dosage of TNX-102 SL, regardless of their treatment assignment in the
lead-in study. No patients, investigators, or study staff will know the assigned study
treatment from the lead-in study, P201, at the time of entry into the extension study.
Patient data collected at the Week 12 visit (Visit 9) in the lead-in P201 study will be used
as one of the baseline values for this study.

Inclusion Criteria:

- Completed the lead-in study and is judged as reasonably compliant, with at least 60%
compliance

- Signed informed consent

- Met all prior inclusion and exclusion requirements for lead-in study

- No new or worsening medical conditions since starting the lead-in study that could
pose a safety risk or interfere with participation in the study

- Willing to refrain from use of specific medication (ask PI)

- Female patients of childbearing potential continue to practice medically acceptable
methods of birth control

Exclusion Criteria: